Hasler G

Molecular Psychiatry Lab, Faculty of Science and Medicine, University of Fribourg, Villars-sur-Glâne, Switzerland.

2 preprints · 18 papers · ORCID

PreprintPsilocybin

Psychedelics Restructure the Global Workspace of Consciousness

Yousefi P, Shinozuka K, Vizeli P +8

Europe PMC2026
ArticlePsilocybin

Adverse Effect-Related Language in Recreational Psychedelic and non-Psychedelic Substance Experience Reports.

Hase A, Erdmann M, Calder A +4

Europe PMC2026
ArticleLSD

Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled study.

Calder AE, Diehl VJ, Lietz MP +7

Europe PMC2026
ArticlePsilocybin

Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.

Beichmann K, Catzeflis P, Aicher HD +4

Europe PMC2026
ArticlePsychedelics

Traumatic Psychedelic Experiences.

Calder AE, Diehl VJ, Hasler G

Europe PMC2026
ArticlePsilocybin

The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences.

Diehl VJ, Calder AE, Hasler G

Europe PMC2026
ArticlePsilocybin

Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis.

Yousefi P, Lietz MP, O'Higgins FJ +4

Europe PMC2025
ArticlePsilocybin

The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample.

Calder AE, Qualls C, Hasler G +2

Europe PMC2025
ArticlePsilocybin

Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis.

Calder AE, Hase A, Hasler G

Europe PMC2025
ArticleKetamine

From antidepressants and psychotherapy to oxytocin, vagus nerve stimulation, ketamine and psychedelics: how established and novel treatments can improve social functioning in major depression.

Kupferberg A, Hasler G

Europe PMC2024
ArticlePsilocybin

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.

Calder AE, Rausch B, Liechti ME +2

Europe PMC2024
ArticleMDMA

Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA.

Calder AE, Hasler G

Europe PMC2024
PreprintMDMA

Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA

Calder A, Hasler G

Europe PMC2024
ArticlePsilocybin

Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.

Rouaud A, Calder AE, Hasler G

Europe PMC2024
ArticlePsychedelics

Extrapharmacological Safety Topics in Psychedelic-Assisted Psychotherapy.

Calder A, Hasler G

Europe PMC2023
ArticlePsilocybin

Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms.

Calder A, Mock S, Friedli N +2

Europe PMC2023
ArticlePsychedelics

Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors.

Ponomarenko P, Seragnoli F, Calder A +2

Europe PMC2023
ArticlePsilocybin

Towards an understanding of psychedelic-induced neuroplasticity.

Calder AE, Hasler G

Europe PMC2023
ArticlePsychedelics

Toward the "helioscope" hypothesis of psychedelic therapy.

Hasler G

Europe PMC2022
ArticlePsilocybin

Analysis of recreational psychedelic substance use experiences classified by substance.

Hase A, Erdmann M, Limbach V +1

Europe PMC2022